Background: A lack of access to methotrexate levels is common in low-and middle-income countries (LMIC), relevant for 80% of children with cancer worldwide. We evaluated whether highdose methotrexate (HD-MTX) can be administered safely with extended hydration and leucovorin rescue, with monitoring of serum creatinine and urine pH.
INTRODUCTION
High-dose methotrexate (HD-MTX) is a commonly used therapeutic agent in patients with acute lymphoblastic leukemia (ALL). A large majority of children with cancers in the world are treated at centres Abbreviations: ALL, acute lymphoblastic lymphoma; ANC, absolute neutrophil count; BMI, body mass index; CTCAE, common terminology criteria for adverse effects; HD-MTX, high-dose methotrexate; ICiCLe, Indian Childhood Collaborative Leukemia Group; LMIC, lowand middle-income country; MTX, methotrexate; T-NHL, T-cell non-Hodgkin lymphoma in low-and middle-income countries (LMIC) that have none or a limited access to performing MTX levels. The standard of care and measures considered mandatory to prevent toxicity of HD-MTX include hydration, alkalinisation, rescue with leucovorin, avoidance of interactive drugs and serial monitoring of serum MTX levels. In a resource rich setting, measurement of a minimum of three MTX levels are recommended, typically performed at 24, 42 and 48 hr from the start of MTX infusion. [1] [2] [3] Based on the serum MTX levels, the volume and duration of hydration, as well as the dose and frequency of leucovorin are titrated. Along with serum MTX levels, serum creatinine, urine output and urine pH are monitored.
There is limited discussion in the literature on the administration of HD-MTX without monitoring MTX levels from centres in LMIC. [4] [5] [6] [7] Local adaptations may be resorted to as an alternative to performing MTX levels. 4 The reported alternative measures include monitoring renal function (e.g., by creatinine clearance, serum creatinine or change in creatinine from baseline) as possible indirect indicator of MTX level or restricting the dose of MTX. 5, 7 The aim was to evaluate if HD-MTX can be administered safely with extended hydration and leucovorin rescue, with monitoring of serum creatinine and urine pH in children with haematological malignancies.
MATERIALS AND METHODS
The prospective study was performed in patients younger than 15 The Indian Childhood Collaborative Leukemia Group (ICiCLe) protocol was followed for the treatment of patients with ALL/T-NHL. 8 HD-MTX was administered, provided the listed criteria were fulfilled: (a) absolute neutrophil count (ANC) ≥750/mm 3 and platelet count ≥100 × 10 9 /l for the first MTX cycle; ANC ≥500/mm 3 and platelet count ≥50 × 10 9 /l for subsequent cycles, (b) serum creatinine < 1.5 times the upper limit of normal, (c) liver transaminases < 10 times the upper limit of normal, and, (d) serum bilirubin < 34.2 mol/l.
MTX infusion and extended leucovorin rescue
The dose of MTX was 3 and 5 gm/m 2 over 24 hr for patients with high-risk B-ALL and T-ALL/T-NHL, respectively. Four cycles of HD-MTX were administered every 14 days. 8 Patients with relapsed ALL received 6 gm/m 2 over 24 hr. A 10% dose of MTX was infused over 30 min, and the remaining 90% over 23.5 hr. Rescue with oral leucovorin (15 mg/m 2 /dose) was initiated 42 hr from the start of MTX infusion. As per the ICiCLe protocol, three doses of leucovorin were to be administered at 42, 48 and 54 hr from the start of MTX infusion; with further doses titrated, as per the MTX levels. Due to the lack of access to MTX levels, three additional doses (total six) of leucovorin were administered at six-hourly intervals empirically to patients enrolled in the study. Patients with relapsed ALL were empirically administered eight doses of leucovorin. Serum creatinine was measured at baseline, 24 and 48 hr of MTX infusion. Urine pH was measured at three time points; after ≥6 hr of alkaline hyperhydration but before the start of HD-MTX, and at 24 and 48 hr after MTX infusion. If the serum creatinine level exceeded 1.25 times the baseline, the hydration was increased to 200 ml/m 2 /hr; subsequently the levels were repeated 12 hourly until the baseline level was attained.
Extended hydration
The patients were administered alkaline hyperhydration at least 6 hr prior to the start of HD-MTX at the rate of 125 ml/m 2 /hr. The hydration fluid was a solution of 0.45% sodium chloride, 5% dextrose with 7.5% sodium bicarbonate (50 mmol/l) and potassium chloride (20 mmol/l).
The urine pH was to be maintained at ≥7 by titrating the sodium bicarbonate in the hydration fluid. The hydration fluid was maintained in parallel during the 24 hr of MTX infusion as well.
As per the standard guidelines, including the ICiCLe protocol, following the end of MTX infusion, hydration is to be continued until leucovorin rescue is completed, provided the MTX levels are optimally reduced at 24, 42 and 48 hr. 8 If MTX levels are above the optimal range, leucovorin rescue and hydration are extended as per explicit guidelines. However, due to the nonavailability of MTX levels, patients with ALL/T-NHL in the study were empirically administered an extended hydration for 72 hr (an additional 42 hr, assuming MTX levels to be optimally reduced) after the completion of MTX infusion. Similarly, for patients with relapsed B-ALL, hydration was continued for 96 hr ( Figure 1 ).
Toxicity criteria
Toxicities were reported as per the National Cancer Institute Common Toxicity Criteria (CTCAE version 4.0). 9 Malnutrition was assessed by the WHO Anthro software v3.2.2 and Anthro plus software v1.0.4 for patients below 5 years and 5-10 years, respectively. 10, 11 For children older than 10 years, the Centre for Disease Control and Prevention (CDC) charts for weight for age were utilized. Weight for age, height for age and body mass index (BMI) for age between −2 and −3 Z score was classified as moderate, and below −3 Z score as severe underweight, stunting and wasting, respectively. 12 Overweight was defined as a BMI of +2 to +3 Z score and obesity as a BMI exceeding +3 Z score.
Statistical analysis
SPSS statistical package v23.0 (SPSS Inc., Chicago, IL) was utilized. An association between categorical variables was evaluated by Fisher's exact or the Chi-square test. All P values were two sided and a value <0.05 was considered significant.
RESULTS
One hundred and six cycles of HD-MTX administered to 59 patients were initially recorded. However, six cycles in six patients were excluded due to either a lack of monitoring of serum creatinine level (n = 4) or a lack of follow-up for assessment of toxicities (n = 2). One hundred cycles of HD-MTX in 53 patients were finally enrolled in the study. The mean age of 53 patients was 6.8 ± 3.2 years (range 1-13).
Forty-five (84.9%) patients were males, with a male to female ratio protocol. Following 48 hr of increase in the volume of hydration, there was a return of serum creatinine level to less than 1.25 times the baseline in 17 (74%) cycles. In the remaining six (26%) cycles, there was a lack of reduction in the creatinine level to <1.25 times the baseline at 48 hr after increasing the volume of hydration to 200 ml/m 2 /hr. However, the serum creatinine was not subsequently measured after 48 hr from the increase in volume of hydration in these six cycles, and the patients were discharged, as the absolute value of serum creatinine was well within range. An increase in serum creatinine to >1.25 times the baseline was not observed to be a risk factor for toxicity.
An influence of several variables on the occurrence of MTX-induced toxicity was evaluated (Table 4) . A higher incidence of neutropenia 
DISCUSSION
The study evaluated the toxicity of HD-MTX administered without monitoring drug level in patients with haematological malignancies. MTX levels in determining rescue measures. 14 Yang et al., from China, evaluated 173 courses of MTX infusion in 54 children with ALL. 15 An elevated creatinine level, high creatinine ratio and decrease of creatinine clearance rate were closely related to delayed MTX elimination. 15 The authors suggested that in settings where MTX concentration detection cannot be performed, creatinine and creatinine clearance rate could be useful tools to identify patients with a high risk of delayed MTX elimination. 15 However, Joannon et al., from Chile, reported a lack of relation between serum MTX concentration and creatinine clearance in 30 children with high-risk non-B ALL. 6 The creatinine clearance was not observed to be a good parameter to calculate leucovorin rescue. MTX-related toxicity inpatients receiving a dose of 1 or 2 gm/m 2 and rescued with leucovorin without monitoring serum MTX levels was acceptable. 6 There is a major concern that excessive hydration and additional doses of leucovorin administered empirically to patients in the absence of MTX drug levels will result in a reduction in the efficacy of HD-MTX.
Indeed, it has been shown that a higher dose of leucovorin is related to a higher risk of relapse in a retrospective study of the Nordic Society of Paediatric Haematology and Oncology (NOPHO). 16 MTX would be necessary to settle the issue. 16 The subject of administration of HD-MTX without MTX levels was debated among select paediatric oncologists and reported in a publication of the Pediatric Hematology Oncology chapter of the Indian Academy of Pediatrics. 17 A few experts advised against the practice, due to the fear of acute renal failure in an occasional patient with high levels. However, it was also argued that prolonged hydration is always warranted when MTX levels are not available and has no impact on the efficacy of HD-MTX, but can prevent toxicity. 17 The majority of patients who need extended leucovorin rescue declare themselves with subtle changes in creatinine, urine output or mucositis. 17 Extending the duration of leucovorin rescue does not impair efficacy since the efficacy of HD-MTX occurs during infusion and until the first dose of leucovorin rescue. 17 Kapoor et al., from New Delhi, have suggested performing at least one drug level (42 hr) for detecting delayed MTX elimination and avoiding its toxicities. 18 It is notable that the mean duration of pre-hydration fluid in our study was extended 13.9 ± 1.87 hr, as against the minimum duration In a recent review, the dilemma of administration of HD-MTX in LMIC lacking an access to MTX levels has been discussed. 19 It has been commented that in centres where MTX levels cannot be monitored, diligent monitoring of urine pH and output, serum creatinine and twice-daily examination of mucosal membranes for evidence of inflammation can allow safe administration of HD-MTX in a majority of patients. 19 Indeed, this practice in Recife, Brazil, where MTX levels were unavailable, allowed for safe administration of hundreds of cycles of HD-MTX. 4 Considering the lack of excessive toxicity in our study, we hypothesize that extra doses of leucovorin could be administered only to patients who experience elevated creatinine level, rather than to all the patients. This approach would need to be tested in a randomized trial in the setting of LMIC.
The death of one patient was due to an incidental, seasonal tropical infectious disease. It is difficult to comment if the immunocompromised status of the patient could have contributed to the severity of the dengue fever. A lack of access to MTX level does not seem to have contributed to the mortality in the patient. The ANC had improved before the patient died, suggesting that mortality was unlikely to have been affected by MTX-induced neutropenia. Dengue fever has been described in patients receiving chemotherapy. [20] [21] [22] To conclude, in centres lacking access to MTX levels, administration of HD-MTX at full doses, with extended hydration, additional doses of leucovorin and monitoring of serum creatinine is feasible with manageable toxicities. The strategy is simple, inexpensive and universally feasible.
